When actionable genomic findings do not translate into treatment in precision oncology
JNCI Cancer Spectrum · 02.11.2026 · 10 (6)
DOI: 10.1093/jncics/pkag115 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 16.10.2026. Verfasst von Ewan K Cobran. Beteiligte Einrichtung: Department of Quantitative Health Science, College of Medicine and Science, Mayo Clinic, Scottsdale, AZ, United States. Hauptthemen laut MEDLINE: Precision Medicine, Neoplasms, Genomics, Medical Oncology. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Comprehensive genomic profiling has expanded the ability to identify potentially actionable molecular alterations across cancers, but identification of an actionable finding does not ensure that a patient will receive a genomically matched therapy. Studies of precision-oncology programs and molecular tumor boards (MTBs) consistently demonstrate substantial attrition between treatment recommendation and treatment initiation. The reasons extend beyond molecular interpretation and include the timing of genomic profiling, clinical deterioration, geographic availability of biomarker-selected trials, insurance and financial barriers, and disparities in access to specialty cancer care. Importantly, these barriers arise after a potentially useful molecular finding has already been identified, creating a distinction between molecular actionability and practical treatment access. This commentary argues that the next implementation challenge for precision oncology is to make clinically meaningful genomic findings realistically actionable. Comprehensive genomic profiling should occur early enough to inform treatment planning; MTB recommendations should be linked to realistic treatment and trial opportunities; financial and insurance barriers should be anticipated when recommendations are made; and equity should be evaluated beyond access to testing to include receipt of genomically informed treatment. As genomic profiling becomes increasingly integrated into routine cancer care, precision oncology should be judged not only by its ability to identify therapeutic opportunities but also by whether patients can reach those opportunities while they remain clinically relevant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Quantitative Health Science, College of Medicine and Science, Mayo Clinic, Scottsdale, AZ, United States.
ORCID-Profile: Ewan K Cobran
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Cobran, E. K. (2026). When actionable genomic findings do not translate into treatment in precision oncology. JNCI Cancer Spectrum, 10(6). https://doi.org/10.1093/jncics/pkag115
Vancouver
Cobran EK. When actionable genomic findings do not translate into treatment in precision oncology. JNCI Cancer Spectrum. 2026;10(6). doi:10.1093/jncics/pkag115
BibTeX
@article{Cobran2026,
author = {Cobran, Ewan K},
title = {When actionable genomic findings do not translate into treatment in precision oncology},
journal = {JNCI Cancer Spectrum},
year = {2026},
volume = {10},
number = {6},
doi = {10.1093/jncics/pkag115}
}
EUVIMED